The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Treatment Failure

 Lipton,  Ali,  Leitzel,  Demers,  Chinchilli,  Engle,  Harvey,  Brady,  Nalin,  Dugan,  Carney,  Allard,  Lanciano,  Calkins,  Bundy,  Parham,  Lucci,  Moore,  Monk,  O'Connor,  Burger,  Hoetelmans,  Hugen,  Mulder,  Meenhorst,  Koopmans,  Brinkman,  Keuter,  Dolmans,  Hekster,  Adams,  Gheorghiade,  Uretsky,  Young,  Ahmed,  Tomasko,  Packer,  Guardiola,  Runde,  Bacigalupo,  Ruutu,  Locatelli,  Boogaerts,  Pagliuca,  Cornelissen,  Schouten,  Carreras,  Finke,  van Biezen,  Brand,  Niederwieser,  Gluckman,  de Witte,  Brabender,  Danenberg,  Metzger,  Schneider,  Park,  Salonga,  Hölscher,  Danenberg,  Mastroianni,  d'Ettorre,  Forcina,  Lichtner,  Mengoni,  D'Agostino,  Corpolongo,  Massetti,  Vullo,  Schirren,  Zachoval,  Gerlach,  Ulsenheimer,  Gruener,  Diepolder,  Baretton,  Schraut,  Rau,  Nitschko,  Pape,  Jung,  Johnson,  Manges,  O'Bryan,  Riley,  Vorwerk,  Mohnike,  Wex,  Röhl,  Zimmermann,  Blum,  Mittler,  Latil,  Bièche,  Vidaud,  Lidereau,  Berthon,  Cussenot,  Vidaud,  Martínez-Jabaloyas,  Gil-Salom,  Villamón-Fort,  Pastor-Hernández,  Martínez-García,  García-Sisamón,  Piketty,  Gérard,  Chazallon,  Marcelin,  Clavel,  Taburet,  Calvez,  Madelaine-Chambrin,  Molina,  Aboulker,  Girard,  Niewoehner,  Erbland,  Deupree,  Collins,  Gross,  Light,  Anderson,  Morgan,  Xing,  Westra,  Tufano,  Cohen,  Rosenbaum,  Rhoden,  Carson,  Vasko,  Larin,  Tallini,  Tolaney,  Holt,  Hui,  Umbricht,  Basaria,  Ewertz,  Tufaro,  Califano,  Ringel,  Zeiger,  Sidransky,  Ladenson,  
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Treatment Failure


Psychiatry related information on Treatment Failure


High impact information on Treatment Failure


Chemical compound and disease context of Treatment Failure


Biological context of Treatment Failure


Anatomical context of Treatment Failure

  • Future research should explore combinations of FU with cisplatin, new radiosensitizers, and active drugs combined with RT to reduce the high rate of pelvic and distant treatment failure still seen in advanced cervix cancer [26].
  • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [27].
  • Serum IGFBP-2 was identified as an independent factor that adds additional information for the prediction of events (relapse or treatment failure) to the conventional prognostic factors such as white blood cell count and platelet count at diagnosis [28].
  • CONCLUSIONS: In patients with recurrent HCV-infection after OLTx, who receive antiviral treatment, a strong, at NS3/4 and NS5 directed and long-lasting CD4+ T cell response is associated with HCV-elimination whereas no or a weak/transient response is associated with treatment failure [29].
  • CONCLUSION: COX-2 is believed to be one of the important factors associated with lymph node involvement and treatment failure [30].

Associations of Treatment Failure with chemical compounds

  • Patients were assessed at 6 months and 12 months, or at the following early end points: drug failure (doubling of creatinine), treatment failure (respiratory or swallowing difficulty), or protocol violation (stopping medication for more than five days) [31].
  • Five per cent of patients given TMP/SMX, 8 per cent of those given TMP, and 49 per cent of those given placebo were considered treatment failures (P less than 0.001 for both active drugs as compared with placebo) [32].
  • Recurrences in eight patients with repeated treatment "failures" were more effectively suppressed with higher doses of acyclovir [33].
  • MAIN OUTCOME MEASURE: Time to asthma treatment failure in patients receiving salmeterol [34].
  • MAIN OUTCOME MEASURE--We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo [35].

Gene context of Treatment Failure

  • Taken together, these data indicate that, although increased expression of the AR gene might play a key role in endocrine treatment failure, it cannot be considered as the sole actor of this unresolved dilemma, and abnormalities in ER alpha and/or ER beta expression may also modulate the growth response of prostate cancer to hormone withdrawal [36].
  • TTP, time to treatment failure, and median survival (17.2 months v 29.6 months) were also significantly shorter in the patients with elevated serum HER-2/neu levels (P <.0001) [37].
  • The multidrug resistance (MDR) phenotype is a major cause of cancer treatment failure [38].
  • Testing of molecular marker coexpression (EGFR and HER2-neu) improves the estimation of prognosis and appears to define low- and high-risk groups for treatment failure in curatively resected NSCLC [39].
  • BRAF mutation was also more frequently associated with absence of tumor I-131 avidity and treatment failure of recurrent disease [40].

Analytical, diagnostic and therapeutic context of Treatment Failure


  1. Bacteriuria in elderly institutionalized men. Nicolle, L.E., Bjornson, J., Harding, G.K., MacDonell, J.A. N. Engl. J. Med. (1983) [Pubmed]
  2. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. Saag, M.S., Powderly, W.G., Cloud, G.A., Robinson, P., Grieco, M.H., Sharkey, P.K., Thompson, S.E., Sugar, A.M., Tuazon, C.U., Fisher, J.F. N. Engl. J. Med. (1992) [Pubmed]
  3. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. Wasson, J.H., Reda, D.J., Bruskewitz, R.C., Elinson, J., Keller, A.M., Henderson, W.G. N. Engl. J. Med. (1995) [Pubmed]
  4. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. Koch, W.M., Brennan, J.A., Zahurak, M., Goodman, S.N., Westra, W.H., Schwab, D., Yoo, G.H., Lee, D.J., Forastiere, A.A., Sidransky, D. J. Natl. Cancer Inst. (1996) [Pubmed]
  5. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Lindor, K.D., Dickson, E.R., Baldus, W.P., Jorgensen, R.A., Ludwig, J., Murtaugh, P.A., Harrison, J.M., Wiesner, R.H., Anderson, M.L., Lange, S.M. Gastroenterology (1994) [Pubmed]
  6. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Hyndiuk, R.A., Eiferman, R.A., Caldwell, D.R., Rosenwasser, G.O., Santos, C.I., Katz, H.R., Badrinath, S.S., Reddy, M.K., Adenis, J.P., Klauss, V. Ophthalmology (1996) [Pubmed]
  7. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis. Simko, V., Michael, S., Prego, V. Am. J. Gastroenterol. (1994) [Pubmed]
  8. Intravenous therapy of metronidazole-resistant Trichomonas vaginalis. Dombrowski, M.P., Sokol, R.J., Brown, W.J., Bronsteen, R.A. Obstetrics and gynecology. (1987) [Pubmed]
  9. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Martínez-Jabaloyas, J.M., Gil-Salom, M., Villamón-Fort, R., Pastor-Hernández, F., Martínez-García, R., García-Sisamón, F. Eur. Urol. (2001) [Pubmed]
  10. Randomized controlled trial in alcohol relapse prevention: role of atenolol, alcohol craving, and treatment adherence. Gottlieb, L.D., Horwitz, R.I., Kraus, M.L., Segal, S.R., Viscoli, C.M. Journal of substance abuse treatment. (1994) [Pubmed]
  11. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Niewoehner, D.E., Erbland, M.L., Deupree, R.H., Collins, D., Gross, N.J., Light, R.W., Anderson, P., Morgan, N.A. N. Engl. J. Med. (1999) [Pubmed]
  12. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. Yee, G.C., Self, S.G., McGuire, T.R., Carlin, J., Sanders, J.E., Deeg, H.J. N. Engl. J. Med. (1988) [Pubmed]
  13. Nifedipine in unstable angina: a double-blind, randomized trial. Gerstenblith, G., Ouyang, P., Achuff, S.C., Bulkley, B.H., Becker, L.C., Mellits, E.D., Baughman, K.L., Weiss, J.L., Flaherty, J.T., Kallman, C.H., Llewellyn, M., Weisfeldt, M.L. N. Engl. J. Med. (1982) [Pubmed]
  14. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. Ingle, J.N., Ahmann, D.L., Green, S.J., Edmonson, J.H., Bisel, H.F., Kvols, L.K., Nichols, W.C., Creagan, E.T., Hahn, R.G., Rubin, J., Frytak, S. N. Engl. J. Med. (1981) [Pubmed]
  15. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. Fisher, B., Carbone, P., Economou, S.G., Frelick, R., Glass, A., Lerner, H., Redmond, C., Zelen, M., Band, P., Katrych, D.L., Wolmark, N., Fisher, E.R. N. Engl. J. Med. (1975) [Pubmed]
  16. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Threlfall, E.J., Ward, L.R., Skinner, J.A., Smith, H.R., Lacey, S. Lancet (1999) [Pubmed]
  17. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Teasley, D.G., Gerding, D.N., Olson, M.M., Peterson, L.R., Gebhard, R.L., Schwartz, M.J., Lee, J.T. Lancet (1983) [Pubmed]
  18. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Nosten, F., ter Kuile, F., Chongsuphajaisiddhi, T., Luxemburger, C., Webster, H.K., Edstein, M., Phaipun, L., Thew, K.L., White, N.J. Lancet (1991) [Pubmed]
  19. A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Johnson, J.R., Manges, A.R., O'Bryan, T.T., Riley, L.W. Lancet (2002) [Pubmed]
  20. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Ringdén, O., Horowitz, M.M., Sondel, P., Gale, R.P., Biggs, J.C., Champlin, R.E., Deeg, H.J., Dicke, K., Masaoka, T., Powles, R.L. Blood (1993) [Pubmed]
  21. Indinavir concentrations and St John's wort. Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M., Falloon, J. Lancet (2000) [Pubmed]
  22. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. List, A.F., Spier, C.S., Grogan, T.M., Johnson, C., Roe, D.J., Greer, J.P., Wolff, S.N., Broxterman, H.J., Scheffer, G.L., Scheper, R.J., Dalton, W.S. Blood (1996) [Pubmed]
  23. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. d'Arminio Monforte, A., Testa, L., Adorni, F., Chiesa, E., Bini, T., Moscatelli, G.C., Abeli, C., Rusconi, S., Sollima, S., Balotta, C., Musicco, M., Galli, M., Moroni, M. AIDS (1998) [Pubmed]
  24. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Davis, B.R., Blaufox, M.D., Oberman, A., Wassertheil-Smoller, S., Zimbaldi, N., Cutler, J.A., Kirchner, K., Langford, H.G. Arch. Intern. Med. (1993) [Pubmed]
  25. Patients with mild heart failure worsen during withdrawal from digoxin therapy. Adams, K.F., Gheorghiade, M., Uretsky, B.F., Young, J.B., Ahmed, S., Tomasko, L., Packer, M. J. Am. Coll. Cardiol. (1997) [Pubmed]
  26. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. Lanciano, R., Calkins, A., Bundy, B.N., Parham, G., Lucci, J.A., Moore, D.H., Monk, B.J., O'Connor, D.M. J. Clin. Oncol. (2005) [Pubmed]
  27. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Marzolini, C., Telenti, A., Decosterd, L.A., Greub, G., Biollaz, J., Buclin, T. AIDS (2001) [Pubmed]
  28. Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. Vorwerk, P., Mohnike, K., Wex, H., Röhl, F.W., Zimmermann, M., Blum, W.F., Mittler, U. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  29. Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination. Schirren, C.A., Zachoval, R., Gerlach, J.T., Ulsenheimer, A., Gruener, N.H., Diepolder, H.M., Baretton, G., Schraut, W., Rau, H.G., Nitschko, H., Pape, G.R., Jung, M.C. J. Hepatol. (2003) [Pubmed]
  30. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Kim, H.J., Wu, H.G., Park, I.A., Ha, S.W. Int. J. Radiat. Oncol. Biol. Phys. (2003) [Pubmed]
  31. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. Tindall, R.S., Rollins, J.A., Phillips, J.T., Greenlee, R.G., Wells, L., Belendiuk, G. N. Engl. J. Med. (1987) [Pubmed]
  32. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. DuPont, H.L., Reves, R.R., Galindo, E., Sullivan, P.S., Wood, L.V., Mendiola, J.G. N. Engl. J. Med. (1982) [Pubmed]
  33. Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment. Straus, S.E., Croen, K.D., Sawyer, M.H., Freifeld, A.G., Felser, J.M., Dale, J.K., Smith, H.A., Hallahan, C., Lehrman, S.N. JAMA (1988) [Pubmed]
  34. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. Lemanske, R.F., Sorkness, C.A., Mauger, E.A., Lazarus, S.C., Boushey, H.A., Fahy, J.V., Drazen, J.M., Chinchilli, V.M., Craig, T., Fish, J.E., Ford, J.G., Israel, E., Kraft, M., Martin, R.J., Nachman, S.A., Peters, S.P., Spahn, J.D., Szefler, S.J. JAMA (2001) [Pubmed]
  35. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. DuPont, H.L., Ericsson, C.D., Mathewson, J.J., de la Cabada, F.J., Conrad, D.A. JAMA (1992) [Pubmed]
  36. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Latil, A., Bièche, I., Vidaud, D., Lidereau, R., Berthon, P., Cussenot, O., Vidaud, M. Cancer Res. (2001) [Pubmed]
  37. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. Lipton, A., Ali, S.M., Leitzel, K., Demers, L., Chinchilli, V., Engle, L., Harvey, H.A., Brady, C., Nalin, C.M., Dugan, M., Carney, W., Allard, J. J. Clin. Oncol. (2002) [Pubmed]
  38. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Turton, N.J., Judah, D.J., Riley, J., Davies, R., Lipson, D., Styles, J.A., Smith, A.G., Gant, T.W. Oncogene (2001) [Pubmed]
  39. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Brabender, J., Danenberg, K.D., Metzger, R., Schneider, P.M., Park, J., Salonga, D., Hölscher, A.H., Danenberg, P.V. Clin. Cancer Res. (2001) [Pubmed]
  40. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Xing, M., Westra, W.H., Tufano, R.P., Cohen, Y., Rosenbaum, E., Rhoden, K.J., Carson, K.A., Vasko, V., Larin, A., Tallini, G., Tolaney, S., Holt, E.H., Hui, P., Umbricht, C.B., Basaria, S., Ewertz, M., Tufaro, A.P., Califano, J.A., Ringel, M.D., Zeiger, M.A., Sidransky, D., Ladenson, P.W. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  41. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Burger, D.M., Hoetelmans, R.M., Hugen, P.W., Mulder, J.W., Meenhorst, P.L., Koopmans, P.P., Brinkman, K., Keuter, M., Dolmans, W., Hekster, Y.A. Antivir. Ther. (Lond.) (1998) [Pubmed]
  42. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Piketty, C., Gérard, L., Chazallon, C., Marcelin, A.G., Clavel, F., Taburet, A.M., Calvez, V., Madelaine-Chambrin, I., Molina, J.M., Aboulker, J.P., Girard, P.M. Antivir. Ther. (Lond.) (2006) [Pubmed]
  43. Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. Mastroianni, C.M., d'Ettorre, G., Forcina, G., Lichtner, M., Mengoni, F., D'Agostino, C., Corpolongo, A., Massetti, A.P., Vullo, V. Blood (2000) [Pubmed]
  44. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Guardiola, P., Runde, V., Bacigalupo, A., Ruutu, T., Locatelli, F., Boogaerts, M.A., Pagliuca, A., Cornelissen, J.J., Schouten, H.C., Carreras, E., Finke, J., van Biezen, A., Brand, R., Niederwieser, D., Gluckman, E., de Witte, T.M. Blood (2002) [Pubmed]
  45. Intensification of background antiretroviral therapy with abacavir during low-level failure may restore optimal suppression. Degen, O., van Lunzen, J., Stellbrink, H.J. Antivir. Ther. (Lond.) (2000) [Pubmed]
WikiGenes - Universities